Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Here’s Why

Akari Therapeutics PLC (NASDAQ:AKTX)’s share price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $9.07 and traded as high as $9.39. Akari Therapeutics shares last traded at $8.94, with a volume of 9,561 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AKTX shares. Maxim Group raised shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Monday, July 20th. Wall Street Zen raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Akari Therapeutics in a report on Friday. Finally, Alliance Global Partners raised Akari Therapeutics to a “strong-buy” rating in a research report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.33.

Akari Therapeutics Stock Performance

The firm’s 50 day simple moving average is $9.07 and its 200-day simple moving average is $9.03.

About Akari Therapeutics

Akari Therapeutics, Plc (NASDAQ: AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on regulating the complement system and inflammatory pathways that contribute to tissue damage.

Akari’s lead investigational product is nomacopan, a recombinant small protein designed to inhibit complement component 5 (C5) and leukotriene B4 (LTB4). The company is also developing a long-acting formulation known as PAS-nomacopan.